Innovative Approaches in the Management of Overactive Bladder (OAB): Managed Care Strategies for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2023 to March 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from

Overactive bladder (OAB) is a highly prevalent condition that approximately 17% of women and 16% of men over 18 suffer from, that’s an estimated 33 million people; however the numbers may be higher due to undiagnosed cases. OAB occurs about twice as frequently in women as in men, and while OAB is not considered a normal part of aging, it does become more prevalent with advanced age. OAB has a significant impact on quality of life (QoL), co-morbidities and cost; sufferers are two to three times more likely to experience disturbed sleep, overeating, poor self-esteem, and depression. This activity will discuss important information regarding the consequences and clinical, societal, and economic burden of underdiagnosed and mismanaged overactive bladder, available data around the optimal cost and efficacy data around treatments and their side-effects, updates on the treatment of NDO in pediatric patients, payer challenges and strategies to achieve optimal cost management and strategies for individualized therapy and improved patient adherence. Attendees will leave with ability to optimize the management of OAB and improve patient adherence and will be able to use that knowledge to educate their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve outcomes and quality of life in patients with overactive bladder.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of overactive bladder (OAB) in terms of health care resource utilization, indirect costs, and member quality of life

  • Discuss communication and diagnostic techniques for early detection and diagnosis of OAB among at-risk patients

  • Compare and contrast the efficacy and safety profiles of new and emerging agents, including the antimuscarinics, beta-3 agonists and combination therapy, in the management of OAB

  • Examine the role of novel treatments for the management of neurogenic detrusor overactivity (NDO) in pediatric patients

  • Review patient factors to consider when selecting between anticholinergics and beta-3 adrenoceptor agonists for OAB treatment

  • Analyze benefit design strategies for clinicians and managed care professionals to improve overall patient outcomes in OAB


Faculty: Matt T. Rosenberg, MD
Mid-Michigan Health Centers
Jackson, Michigan


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Rosenberg has served as a consultant for Astellas and Urovant. He serves on the speaker's bureau for Astellas and Urovant. His presentation has been peer reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue